Clinical Trial Update: Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1) [Phase 3]

View source ↗

Summary

Phase 3 trial OTEMTO 1 evaluated a fixed-dose combination of tiotropium and olodaterol for chronic obstructive pulmonary disease; results were posted after comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Spiriva (tiotropium)
• Striverdi Respimat (olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2015-11-25